Physician profile
Joseph Ho
NPI 1962766451
$2,681.67
in general payments reported to CMS, 2019-2025
17 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $71.51 · 2021: $308 · 2022: $248 · 2023: $1,213 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,100 · Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,100.00 |
| Food and Beverage | $234.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,100.00 | 2023 | Eylea |
| Alcon Vision LLC | $206.70 | 2019 | |
| Novo Nordisk INC | $200.40 | 2022-2025 | Wegovy |
| Abbvie INC. | $169.19 | 2022 | |
| Carl Zeiss Meditec, INC. | $127.31 | 2019 | |
| Allergan, INC. | $126.74 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $126.55 | 2021 | |
| Genentech USA, INC. | $124.13 | 2021 | |
| Apellis Pharmaceuticals, INC. | $113.30 | 2023 | Syfovre |
| Lilly USA, LLC | $104.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $102.90 | 2019 | |
| Eisai INC. | $58.06 | 2020 | |
| Daiichi Sankyo INC. | $36.95 | 2019 | |
| Aerie Pharmaceuticals, INC. | $34.45 | 2021 | |
| Glaukos Corporation | $22.47 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.77 | 2019 | |
| Indivior INC. | $13.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.